Bronchopulmonary Dysplasia - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bronchopulmonary Dysplasia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Bronchopulmonary Dysplasia - Pipeline Review, H1 2016', provides an overview of the Bronchopulmonary Dysplasia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia
- The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects
- The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bronchopulmonary Dysplasia Overview 7
Therapeutics Development 8
Pipeline Products for Bronchopulmonary Dysplasia - Overview 8
Bronchopulmonary Dysplasia - Therapeutics under Development by Companies 9
Bronchopulmonary Dysplasia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bronchopulmonary Dysplasia - Products under Development by Companies 13
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development 14
Airway Therapeutics, Inc. 14
AstraZeneca Plc 15
Chiesi Farmaceutici SpA 16
MediPost Co., Ltd. 17
Syntrix Biosystems, Inc. 18
Therabron Therapeutics, Inc. 19
Bronchopulmonary Dysplasia - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AT-100 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
budesonide - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CG-100 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drugs for Bronchopulmonary Dysplasia - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
gefitinib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Pneumostem - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
R-190 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
R-801 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
R-901 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
R-908 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SX-576 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Bronchopulmonary Dysplasia - Recent Pipeline Updates 52
Bronchopulmonary Dysplasia - Dormant Projects 54
Bronchopulmonary Dysplasia - Discontinued Products 55
Bronchopulmonary Dysplasia - Product Development Milestones 56
Featured News & Press Releases 56
Mar 02, 2016: Therabron Therapeutics Announces New Study Aimed at the Creation of Multiple Novel Isoforms of the Company Lead Product Candidate 56
Dec 08, 2015: Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial 56
Oct 20, 2015: Therabron Therapeutics Receives Notice of Allowance for New EU Patent Supporting its Recombinant CC10 Technology Platform 57
Jul 21, 2015: Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program 57
May 13, 2015: Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia 58
Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung 58
Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial 59
Jul 29, 2014: Lung disease stem cell drug designated 'orphan drug in development stage' 59
Feb 06, 2014: Stem cells to treat lung disease in preterm infants 60
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables
Number of Products under Development for Bronchopulmonary Dysplasia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Bronchopulmonary Dysplasia - Pipeline by Airway Therapeutics, Inc., H1 2016 14
Bronchopulmonary Dysplasia - Pipeline by AstraZeneca Plc, H1 2016 15
Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2016 16
Bronchopulmonary Dysplasia - Pipeline by MediPost Co., Ltd., H1 2016 17
Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems, Inc., H1 2016 18
Bronchopulmonary Dysplasia - Pipeline by Therabron Therapeutics, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Bronchopulmonary Dysplasia Therapeutics - Recent Pipeline Updates, H1 2016 52
Bronchopulmonary Dysplasia - Dormant Projects, H1 2016 54
Bronchopulmonary Dysplasia - Discontinued Products, H1 2016 55